Alar Pharmaceuticals Inc. (TPEX:6785)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
117.00
+1.50 (1.30%)
Apr 24, 2025, 1:30 PM CST
-60.74%
Market Cap 7.72B
Revenue (ttm) 5.82M
Net Income (ttm) 18.17M
Shares Out 66.80M
EPS (ttm) 0.27
PE Ratio 424.62
Forward PE n/a
Dividend 0.25 (0.22%)
Ex-Dividend Date n/a
Volume 38,148
Average Volume 172,779
Open 117.00
Previous Close 115.50
Day's Range 116.50 - 118.00
52-Week Range 108.50 - 300.50
Beta 0.12
RSI 35.34
Earnings Date May 9, 2025

About Alar Pharmaceuticals

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson’s disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan. [Read more]

Sector Healthcare
Founded 2016
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6785
Full Company Profile

Financial Performance

In 2024, Alar Pharmaceuticals's revenue was 5.82 million, a decrease of -98.76% compared to the previous year's 469.27 million. Earnings were 18.17 million, a decrease of -95.25%.

Financial Statements

News

There is no news available yet.